본문으로 건너뛰기
← 뒤로

Metabolic Reprogramming of T Cells by Dual UCP2 and IL-17 Blockade Enhances Immunity Against Pancreatic Cancer.

1/5 보강
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 📖 저널 OA 92.8% 2023: 1/1 OA 2024: 12/12 OA 2025: 148/154 OA 2026: 278/306 OA 2023~2026 2026 Vol.13(16) p. e13020 OA
Retraction 확인
출처

Liu CT, Yeh CC, Wu TC, Lin CH, Kuo YT, Iwakura Y

📝 환자 설명용 한 줄

Pancreatic ductal adenocarcinoma (PDAC) remains resistant to immunotherapy due to its immunosuppressive tumor microenvironment (TME) and impaired metabolic fitness of effector T cells.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Liu CT, Yeh CC, et al. (2026). Metabolic Reprogramming of T Cells by Dual UCP2 and IL-17 Blockade Enhances Immunity Against Pancreatic Cancer.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(16), e13020. https://doi.org/10.1002/advs.202513020
MLA Liu CT, et al.. "Metabolic Reprogramming of T Cells by Dual UCP2 and IL-17 Blockade Enhances Immunity Against Pancreatic Cancer.." Advanced science (Weinheim, Baden-Wurttemberg, Germany), vol. 13, no. 16, 2026, pp. e13020.
PMID 41486584 ↗

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains resistant to immunotherapy due to its immunosuppressive tumor microenvironment (TME) and impaired metabolic fitness of effector T cells. Here, we show that targeting UCP2 reprograms T-cell metabolism, and that dual blockade with IL-17 further enhance antitumor responses in PDAC. Pharmacologic UCP2 inhibition with genipin increases IFN-γ production by CD8⁺ T cells through IL-12R/STAT4/mTOR signaling and enhanced mitochondrial oxidative phosphorylation, promoting a T-bet-driven cytotoxic program. However, UCP2 inhibition alone does not suppress tumor growth. Accordingly, combination with IL-17 depletion synergistically augments Tc1/Th1 responses, reduces myeloid-derived suppressor cells (MDSCs), and improves survival across multiple PDAC models, including genetically engineered and orthotopic systems. CD8⁺ T-cell depletion abrogates these effects. Moreover, UCP2 inhibition enhances IFN-γ production in patient-derived PBMCs and tumor-infiltrating lymphocytes. These findings identify UCP2 as a metabolic checkpoint in cytotoxic T cells and support dual UCP2/IL-17 blockade as a promising immunotherapeutic strategy for PDAC.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기